Akademik Veri Yönetim Sistemi
Seminars in Ophthalmology, 2026 (SCI-Expanded, Scopus)
Purpose: To evaluate long-term intraocular pressure (IOP), number of antiglaucoma medications (AGMs), and success after phacoemulsification combined with XEN-45 implantation (Phaco+XEN-45), and to compare these outcomes between primary open-angle glaucoma (POAG) and pseudoexfoliation glaucoma (PEXG). Methods: This retrospective study included 30 patients (30 eyes; 17 POAG, 13 PEXG) who underwent Phaco+XEN-45 implantation. IOP, number of AGMs, postoperative interventions, complete or qualified surgical success (IOP of 5–18 mmHg with AGMs or independent of AGMs, respectively), and failure (failure to achieve qualified success) were evaluated at 1, 2, 3, 4, 5 years postoperatively and at the final follow-up. Results: The median IOP at baseline was 20.5 (14.8–26.5) mmHg and decreased to 16.0 (14.8–17.3) mmHg at 5 years. The median number of AGMs decreased from 3.0 (2.0–3.3) at baseline to 2.0 (0.0–2.3) at 5-year, presenting a significant reduction at all follow-up time points (p <.001). The median IOP did not differ between POAG and PEXG during follow-up, whereas PEXG required more AGMs at 1 and 2 years (p =.048 and p =.031, respectively). Kaplan-Meier analysis showed complete success rates of 60% and 36% and qualified success rates of 100% and 96%, at 1 and 5 years, respectively; with 70% qualified success rate at 8 years. Long-term success did not differ between the POAG and PEXG groups. Conclusion: Phaco+XEN-45 implantation offers a significant reduction in AGMs and a marked decrease in IOP, with an acceptable long-term efficacy and safety profile. The similarity in the success rates of POAG and PEXG suggests that Phaco+XEN-45 is a feasible and safe option for both types of glaucoma with appropriate patient selection and effective postoperative bleb modulation.